<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03070405</url>
  </required_header>
  <id_info>
    <org_study_id>16-0138</org_study_id>
    <nct_id>NCT03070405</nct_id>
  </id_info>
  <brief_title>The Effect of PAS on the Pharmacokinetics of Tenofovir in Healthy Subjects</brief_title>
  <official_title>An Open-label, Randomized, Crossover Study to Evaluate the Effect of PAS on the Pharmacokinetics of Tenofovir in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inje University</source>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate whether PAS will change the PK parameters of
      tenofovir.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak plasma concentration (Cmax) of tenofovir</measure>
    <time_frame>0-84 hours in test and 0-72 hours in reference arm</time_frame>
    <description>Cmax of Tenofovir will be compared between test and reference arms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of tenofovir</measure>
    <time_frame>0-84 hours in test and 0-72 hours in reference arm</time_frame>
    <description>AUC of tenofovir will be compared between test and reference arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution of tenofovir</measure>
    <time_frame>0-84 hours in test and 0-72 hours in reference arm</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of peak plasma concentration(Tmax) of tenofovir</measure>
    <time_frame>0-84 hours in test and 0-72 hours in reference arm</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma half-life of tenofovir</measure>
    <time_frame>0-84 hours in test and 0-72 hours in reference arm</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance of tenofovir</measure>
    <time_frame>0-24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of tenofovir excreted in urine</measure>
    <time_frame>0-24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration of PAS</measure>
    <time_frame>0-12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of PAS</measure>
    <time_frame>0-12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance of PAS</measure>
    <time_frame>0-12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution of PAS</measure>
    <time_frame>0-12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of peak plasma concentration of PAS</measure>
    <time_frame>0-12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma half-life of PAS</measure>
    <time_frame>0-12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of PAS excreted in urine</measure>
    <time_frame>0-12 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Tenofovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenofovir disoproxil fumarate 300mg single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tenofovir + PAS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir disoproxil fumarate 300mg single dose, Para-aminosalicylic acid Ca Granule 5.28 g BID seven dose administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate 300mg</intervention_name>
    <description>Single oral dose on the first day of each period</description>
    <arm_group_label>Tenofovir</arm_group_label>
    <arm_group_label>Tenofovir + PAS</arm_group_label>
    <other_name>viread</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Para-aminosalicylic acid Ca granule 5.28 g</intervention_name>
    <description>Twice daily oral administration from the first day of each period to the seventh dose</description>
    <arm_group_label>Tenofovir + PAS</arm_group_label>
    <other_name>Pas Granule Dongindang</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult male volunteers, ages 19 to 45 years at the time of screening test
             inclusive.

          2. Subjects who did not have congenital or chronic diseases and sign and symptom after
             medical examinations

          3. Body Mass Index (BMI) of 18 to 25 kg/m2, inclusive. BMI = weight (kg)/ [height (m)]2.

          4. Volunteers deemed as appropriate subjects by investigators, after passing medical
             screening, including assessment of medical history, vital signs, 12-lead ECG, physical
             examination, laboratory tests etc. according to the characteristics of the
             investigational products.

          5. Subjects who can participate in the whole clinical trial.

          6. Subjects who voluntarily sign a written consent form after having received information
             regarding the objectives and contents of the trial, and characteristics of the study
             drug drugs prior to signing.

        Exclusion Criteria:

          1. Medical History

               1. Subjects with any disease or history of clinically significant liver, kidney,
                  digestive system, respiratory system, musculoskeletal system, endocrine system,
                  neuropsychiatric system, hemato-oncologic system, urinary system, cardiovascular
                  system including arrhythmia.

               2. Subjects with any history of gastrointestinal diseases/conditions that could
                  impact on the absorption of study drug.

          2. Laboratory Test and ECG Findings

               1. Subjects who show, or have had clinical abnormalities detected through laboratory
                  tests prior to the trial commencement date. Criteria for liver and renal function
                  test are shown below:

                    -  AST or ALT above 1.25×ULN

                    -  Total bilirubin above 1.5×ULN

                    -  Serum creatinine clearance calculated by CKD-EPI below 80mL/min

               2. Subjects who show a clinically significant abnormalities detected through ECG

          3. History of hypersensitivity to the drug including study drug ingredients and other
             medications (aspirin, antibiotics, etc.) or clinically significant hypersensitivity

          4. Prohibition on Concomitant Drug/Food

               1. Use of ethical-the-counter/herbal preparations or use of over-the-counter
                  medications/vitamin medications within 2 weeks or 1 week prior to study drug
                  administration, respectively

               2. Subjects on any diet which could affected study drug's pharmacokinetics

               3. Subjects who administered the Probenecid, Penicillin G and other drugs which
                  already known has an effect on OAT1 Transporter activity within 2 weeks prior to
                  the first dose.

          5. Blood Donation and Transfusion

               1. Donation of blood or plasma to a blood bank or in a clinical study (except a
                  screening visit) within 60 days prior to study drug administration.

               2. Blood transfusion within 30 days prior to study drug administration.

          6. Other Exclusion Criteria

               1. Alcohol over intake (alcohol &gt; 30g/day) and screening positive for alcohol

               2. Subjects who smoke within 3 months before initiation of clinical trial and
                  subjects who cannot stop smoking during the participation of clinical study

               3. Subjects who cannot stop taking caffeine-containing foods (e.g. coffee, tea,
                  green tea, cocoa, chocolate, soda, coffee milk, energy supplementary beverage,
                  etc.) and alcoholic beverage during the participation of clinical study

               4. Subjects deemed to be inappropriate for the trial as determined by the
                  investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male participants included into the study</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-Gook Shin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2017</study_first_submitted>
  <study_first_submitted_qc>March 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <last_update_submitted>March 2, 2017</last_update_submitted>
  <last_update_submitted_qc>March 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Inje University</investigator_affiliation>
    <investigator_full_name>Jae-Gook Shin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Tenofovir Disoproxil Fumarate</keyword>
  <keyword>4-Aminosalicylic Acid</keyword>
  <keyword>Tuberculosis</keyword>
  <keyword>HIV</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Aminosalicylic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

